OrganOx, an Oxford, UK-based organ medical technology company, raised $142M in equity funding.
The round was led by new investor HealthQuest Capital with participation from existing investors BGF and Lauxera Capital Partners, along with additional new investors Sofina, Soleus Capital, and Avidity Partners. Existing investors included the University of Oxford, Technikos, the Oxford Technology and Innovations Fund, and Longwall Ventures.
The company intends to use the funds to accelerate growth opportunities for its metra® platform technology in the organ technology global market.
Led by Oern R. Stuge, MD, MBA, and Executive Chairman, OrganOx is a commercial stage organ technology company, spun out of the University of Oxford in 2008, dedicated to developing technologies to improve outcomes for patients with acute or chronic organ failure. The OrganOx metra® is a normothermic machine perfusion (NMP) platform approved in the U.S., Europe, Canada, and Australia. It has been utilized in over 5,000 liver transplants to date to keep donor livers in a metabolically active state outside the body so that functional assessment of the organ can be performed prior to transplant, leading to an increased number of organs available for transplant.
The company also has an investigational metra® technology for kidney transplants which is expected to soon begin U.S. clinical trials. Further, in partnership with eGenesis, Inc., OrganOx expects to begin a first-in-human clinical study of the use of its metra® technology combined with eGenesis’ genetically engineered porcine livers to support patients with acute-on-chronic liver failure.
FinSMEs
24/02/2025